Arcellx Inc. Common Stock (ACLX)

FairStock Score: 16/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At the 2026-05-15 close, Arcellx carried a $6.7B market cap and a $115.07 share price, near the top of its 52-week range of $60.35 to $115.13. This is not a business in the Graham sense: in the latest reported quarter, fiscal Q4 2025, revenue was $1.7M and net income was -$58.1M. Trailing free cash flow was -$212.6M, for a FairStock FCF yield of -3.2%. The company has low leverage, with debt-to-equity of 0.13, and an Altman Z-Score of 18.71, so balance-sheet distress is not the immediate concern. But returns are poor: ROE is -53.42% and ROCE is -24.05%. The Piotroski F-Score is 1/9, and FairStock's overall score is 16/100. The provided revenue growth of -89.17% and profit growth of -23.43% show how lumpy and weak current commercial traction is. The investment case rests almost entirely on clinical execution: anitocabtagene autoleucel is in Phase 2 for relapsed or refractory multiple myeloma, with earlier-stage assets behind it. A durable moat is not yet visible; in biotech, the moat is usually patents, data, manufacturing, and approved products, and none is proven here by the numbers. Valuation is not anchored by earnings or book value: P/E is negative at -28.27, P/B is 16.56, and the FairStock Lynch category is 'none' because there are only 0 years of filed results. As a Buffett-style investor, I would call this a speculative pipeline bet, not a proven compounding machine. Without margin of safety from current cash flows, the price depends on future milestones.

In plain English: This company is an early-stage biotechnology firm trying to develop cell therapies for cancer. It currently brings in very little money and loses much more than it earns, and the share price is near its 52-week high even though sales and profits look weak. Based on the numbers provided, the price looks expensive compared with the current business, so future trial results are doing most of the work.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-05-15 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer